Clinical Trials Directory

Trials / Completed

CompletedNCT07418138

Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation

Efficacy and Safety of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation

Status
Completed
Phase
Study type
Observational
Enrollment
484 (actual)
Sponsor
Hu Liangshuo · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Based on the follow-up data of hepatocellular carcinoma (HCC) patients undergoing liver transplantation from the China Liver Transplant Registry (CLTR) and the First Affiliated Hospital of Xi'an Jiaotong University, patients who met the inclusion criteria were assessed for tumor response, post-transplant tumor recurrence, and survival rates. Statistical analysis was performed to evaluate patient prognosis and to identify risk factors affecting outcomes.

Detailed description

A retrospective study was performed on patients who underwent liver transplant for hepatocellular carcinoma (HCC) at the First Affiliated Hospital of Xi'an Jiaotong University between January 2015 and December 2024. Clinical data including demographic characteristics, tumor characteristics, detailed history of pre-transplant antitumor therapy, perioperative laboratory parameters, surgical details, and pathological findings were collected from the hospital's prospective clinical database. Based on follow-up records, patients who met the inclusion criteria were evaluated for tumor response, post-transplant tumor recurrence and overall survival. Statistical analyses were conducted to assess postoperative prognosis and to identify risk factors associated with clinical outcomes.

Conditions

Interventions

TypeNameDescription
OTHERMedication historyThe study was retrospective and did not involve the application of interventions.
OTHERMedication historyThe study was retrospective and did not involve the application of interventions

Timeline

Start date
2015-01-01
Primary completion
2024-12-31
Completion
2024-12-31
First posted
2026-02-18
Last updated
2026-02-18

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07418138. Inclusion in this directory is not an endorsement.